Investigation of Actinium Pharmaceuticals, Inc.
Pomerantz LLP is currently looking into claims for investors of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). The investigation aims to find out if Actinium, along with some of its officers or directors, engaged in any illegal business activities, including potential securities fraud.
Call for Investors to Step Forward
If you're an Actinium shareholder who believes you've been impacted, it's vital to reach out to representatives at Pomerantz LLP. They are dedicated to providing investors with the essential guidance and support during this investigation.
Recent Regulatory Issues
Update on Biologics License Application
Recently, Actinium provided a regulatory update on its Biologics License Application (BLA) for Iomab-B, which is intended for patients with active relapsed or refractory acute myeloid leukemia (r/r AML). This update revealed that the U.S. Food and Drug Administration (FDA) found the Phase 3 SIERRA trial insufficient to support the BLA filing, despite the trial hitting its statistically significant primary endpoint.
Effect on Stock Value
This regulatory news significantly affected the company's stock price, resulting in a sharp drop of $3.69, which translates to a 59.81% decrease in value. As a consequence, the stock closed at $2.48.
About Pomerantz LLP
Pomerantz LLP stands out as a prominent law firm that specializes in corporate, securities, and antitrust class-action litigation. Founded over 85 years ago by the late Abraham L. Pomerantz, the firm has earned a strong reputation for standing up for the rights of victims of securities fraud and other corporate wrongdoing. Their commitment to recovering damages for class members is impressive, having secured billions of dollars in settlements over the years.
Frequently Asked Questions
What is the focus of the investigation by Pomerantz LLP?
Pomerantz LLP is investigating potential securities fraud and illegal business practices involving Actinium Pharmaceuticals and its management team.
How has the recent regulatory update affected Actinium's stock?
The regulatory update led to a dramatic decline in Actinium's stock price, with a drop of 59.81% following the announcement.
Who should investors contact regarding the investigation?
Investors are encouraged to reach out to Pomerantz LLP to voice their concerns and discuss their exposure related to the ongoing investigation.
What does an inadequate FDA trial result mean for Actinium?
An inadequate trial result from the FDA can impede a company's chances of filing for vital drug approvals, thus affecting its growth prospects and stability in the market.
What has been Pomerantz LLP's track record?
Pomerantz LLP is well-regarded for obtaining substantial damages for victims of corporate misconduct, establishing a significant legacy in securities litigation with billions in settlements awarded.
